Browse drugs

…ore recent cohorts (p=0.001).Conclusion Earlier introduction of azathioprine after corticosteroid therapy resulted in a higher rate of trans…

…tic reports. In the short term, alpha-2 agonists, amphetamines, atomoxetine, methylphenidate, and viloxazine showed medium to large effect …

…nd 0.49 (95% CI 0.41 to 0.58) to 0.93 (95% CI 0.72 to 1.20) for SGLT2i. Prescriptions for both ARNi and SGLT2i showed a social gradien…

… 52.1%.Conclusions Nelmastobart plus trifluridine/tipiracil and bevacizumab was well tolerated, with no drug-related toxicities. BTN1A1 exp…

…unother Cancer. 2019;7:214.Wong MK, Milhem MM, Sacco JJ, et al. RP1 combined with nivolumab in advanced anti-PD-1-failed melanoma (…

…sions First-line treatment with serplulimab in combination with bevacizumab and chemotherapy demonstrated promising antitumor activity and …

…114 male and 50 female (unspecified 17). The ICIs involved were nivolumab (n=68), pembrolizumab (n=51), ipilimumab (n=35), atezolizumab (…

…tor memory phenotype compared to GD2BBζ CAR-T cells (figure 1). GD2BBDAP12 CAR-T cells also had significantly reduced downregulation of CD…

… a 8.3 month increase in median overall survival when receiving ICI+C versus ICI alone, whereas patients with a low score (∆TRI ≤16, …

…ansen JS, Larsen FO, Theile S, Hasselby JP, Willemoe GL, et al. Nivolumab with or without ipilimumab combined with stereotactic body radi…

…cancer (NSCLC) patients with mutated KRAS in a phase 2 trial of mecbotamab vedotin (CAB-AXL-ADC). Presented at: European Lung Cancer Congress; 202…

…esting a reset of the immune switch toward anti-tumor immunity. VP-315 is a promising treatment for non-surgical first line BCC therap…